Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lipoprotein (a)]

A Piolot1, B Jacotot

  • 1Service de Médecine interne, Nutrition, Métabolisme des Lipides, CHU Henri-Mondor, Créteil.

Presse Medicale (Paris, France : 1983)
|October 22, 1994
PubMed
Summary
This summary is machine-generated.

High lipoprotein(a) [Lp(a)] levels, influenced by genetics, significantly increase the risk of ischemic heart disease and atherosclerosis. Effective treatments to lower Lp(a) are limited.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial).

Annals of oncology : official journal of the European Society for Medical Oncology·2003
Same author

Moderate intake of n-3 fatty acids is associated with stable erythrocyte resistance to oxidative stress in hypertriglyceridemic subjects.

The American journal of clinical nutrition·2001
Same author

[Role of diet in cardiovascular prevention].

Annales de medecine interne·2001
Same author

Effect of an alpha-blocker (Nicergoline) and of a beta-blocker (Acebutolol) on the in vitro biosynthesis of vascular extracellular matrix.

Pathologie-biologie·2001
Same author

Autosomal dominant type IIa hypercholesterolemia: evaluation of the respective contributions of LDLR and APOB gene defects as well as a third major group of defects.

European journal of human genetics : EJHG·2000
Same author

[The hyperlipidemias. What remains of the Fredrickson classification?].

Presse medicale (Paris, France : 1983)·1999
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Area of Science:

  • Biochemistry
  • Genetics
  • Cardiovascular Medicine

Context:

  • Lipoprotein(a) [Lp(a)] shares similarities with low-density lipoproteins (LDL) but includes apo-lipoprotein(a) [apo(a)].
  • The apo(a) structure resembles plasminogen, with described genetic polymorphisms.
  • Plasma Lp(a) levels exhibit significant inter-individual variation, primarily due to genetic factors.

Purpose:

  • To highlight the clinical significance of lipoprotein(a) [Lp(a)].
  • To underscore the correlation between elevated Lp(a) levels and ischemic heart disease.
  • To discuss the genetic determinants of Lp(a) isoforms and their impact on plasma levels.

Summary:

  • Lipoprotein(a) [Lp(a)] is an LDL-like particle containing apo-lipoprotein(a) [apo(a)], with a structure similar to plasminogen.

Related Experiment Videos

  • Elevated Lp(a) levels, particularly above 30 mg/dL, are strongly associated with increased risk for atherosclerosis-related diseases.
  • Genetic factors heavily influence Lp(a) levels and isoforms, contributing to its variability.

    • Impact:

    • Increased understanding of Lp(a)'s role in cardiovascular disease pathogenesis.
    • Highlights the need for effective therapeutic strategies to manage elevated Lp(a) levels.
    • Emphasizes the genetic basis of Lp(a) levels and associated cardiovascular risk.